|
A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301)
|
|
U24-235-2
|
|
A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301)
|
|
Dr. Margaret Callahan
|
|
The main purpose of this research study is to learn if the study drug, brenetafusp (IMC-F106C), in combination with a standard therapy (nivolumab), works better than the standard therapy (nivolumab alone or in combination with relatlimab) at making tumors stop growing (or shrink) in patients with advanced melanoma.
|
Cancer - Skin
|
|
|
Check with study contact
|
|
Kristen Grandonico. Telephone: 860-679-6580. Email: grandonico@uchc.edu
|
|
Enrolling/recruiting.
|
|
|